{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Membrane Transporter & Ion Channel > AzelnidipineCAS：123524-52-7
Molecular Formula：C33H34N4O6
Molecular Weight：582.65
Storage：Powder:-20℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥98%
Appearance：Light yellow Solid
Qty：
Size：
| CAS | 123524-52-7 |
| Name | Azelnidipine |
| Molecular Formula | C33H34N4O6 |
| Molecular Weight | 582.65 |
| Solubility | Soluble in DMSO ≥10mg/mL |
| Purity | ≥98% |
| Appearance | Light yellow Solid |
| Storage | Powder:-20℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| EC | EINECS 634-143-0 |
| MDL | MFCD00865803 |
| SMILES | CC1=C(C(C(=C(N1)N)C(=O)OC2CN(C2)C(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC(C)C |
| Target Point | Calcium Channel |
| Passage | Membrane Transporter&Ion Channel;Neuronal Signaling |
| Background | It is a dihydropyridine derivative and is an L-type calcium channel blocker. |
| Biological Activity | Azelnidipine是一种二氢吡啶类钙通道阻断剂。[1] |
| In Vitro | Azelnidipine是一种新开发的长效钙通道阻断剂，具有独特的药理学特性，例如使心跳减慢和对维管组织的高亲和力，这些特性使它与其它的钙通道阻断剂有所不同，因此Azelnidipine成为新一代钙通道阻断剂可以用来治疗高血压，不管病人是否具有缺血性心脏病的风险。由于它的高脂溶性使得它从血液中被清除后仍然可以留在血管壁当中继续发挥降血压的功效。[1] |
| In Vivo | AZL itself exhibited little effect on myocyte mechanics but it significantly alleviated STZ-induced myocyte contractile dysfunction. All of these STZ-induced alterations were reconciled by AZL treatment. Collectively，the data suggest beneficial effect of AZL in diabetic cardiomyopathy via altering intracellular Ca2+ handling proteins and preventing apoptosis by its antioxidant property.[2] |
| Cell Experiment | Six to eight-week-old male Wistar rats(NCCS，Pune，India)，weighing 250 to 280 g，were made diabetic by single intra-peritoneal(IP)injection of streptozotocin(STZ)(55 mg/kg). Control animals were treated with vehicle(0.1 mol/L sodium citrate buffer，pH4.5). Hyperglycemia(blood glucose > 200 mg/dL)was confirmed 3 days post STZ injection using a glucometer. Diabetic animals were treated with single dose of 5 mg/kg AZL suspended in 1% carboxy methyl cellulose，administered orally by gavage，starting the 4th day of STZ treatment(n = 12)daily for a period of 12 weeks. Blood glucose and body weight were measured weekly and at the end of the study.[2] |
| Data Literature Source | [1]. Komoda H，Inoue T，Node K. Anti-inflammatory properties of azelnidipine，a dihydropyridine-based calcium channel blocker. Clin Exp Hypertens. 2010 Jan;32(2):121-8. [2]. Kain V，Kumar S，Sitasawad SL. Azelnidipine prevents cardiac dysfunction in streptozotocin-diabetic rats by reducing intracellular calcium accumulation，oxidative stress and apoptosis. Cardiovasc Diabetol. 2011 Nov 4;10:97. |
| Unit | Bottle |
| Specification | 5mg 10mM*1mL in DMSO 10mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
